Axonics Nabs CE Mark for Sacral Neuromodulation System
Axonics Modulation Technologies has scooped up CE marking for its rechargeable implantable Sacral Neuromodulation System for the treatment of urinary and fecal dysfunction.
A peer-reviewed study found the system could save the U.S. healthcare system more than $12 billion over the next 15 years.
The company has also received ethics committee approval from select centers in Western Europe to start a 65-patient post-market clinical follow up study of the device. — Michael Cipriano